Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29356031 | 0.99 | ERN1 (0.99) | ERN1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL22190836 | 0.99 | ERN1 (0.99) | ERN1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL29356029 | 0.99 | ERN1 (0.99) | ERN1ADORA2AADORA1 | |
| SCHEMBL22190683 | 0.93 | ERN1 (0.87) | ERN1ADORA2AADORA1 | |
| SCHEMBL29353630 | 0.93 | ERN1 (0.87) | ERN1ADORA2AADORA1 | |
| SCHEMBL22190767 | 0.92 | ERN1 (0.85) | ERN1 | |
| SCHEMBL29355924 | 0.92 | ERN1 (0.85) | ERN1 | |
| SCHEMBL22190617 | 0.90 | ERN1 (0.82) | ERN1 | |
| SCHEMBL29355776 | 0.90 | ERN1 (0.82) | ERN1 | |
| SCHEMBL22190543 | 0.88 | ERN1 (0.79) | ERN1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885ADORA2A 275/4885ADORA1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.